A detailed history of Jpmorgan Chase & CO transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 669,105 shares of NTLA stock, worth $10.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
669,105
Previous 543,107 23.2%
Holding current value
$10.1 Million
Previous $14.9 Million 0.23%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$20.02 - $27.22 $2.52 Million - $3.43 Million
125,998 Added 23.2%
669,105 $15 Million
Q1 2024

May 10, 2024

SELL
$23.82 - $32.8 $2.22 Million - $3.05 Million
-93,010 Reduced 14.62%
543,107 $14.9 Million
Q4 2023

Feb 12, 2024

BUY
$23.16 - $32.34 $488,699 - $682,406
21,101 Added 3.43%
636,117 $19.4 Million
Q3 2023

Nov 14, 2023

SELL
$31.62 - $45.78 $1.21 Million - $1.75 Million
-38,334 Reduced 5.87%
615,016 $19.4 Million
Q2 2023

Aug 11, 2023

SELL
$34.58 - $46.03 $614,901 - $818,505
-17,782 Reduced 2.65%
653,350 $26.6 Million
Q1 2023

May 18, 2023

BUY
$33.3 - $44.82 $3.66 Million - $4.93 Million
109,960 Added 19.59%
671,132 $25 Million
Q1 2023

May 11, 2023

SELL
$33.3 - $44.82 $3.38 Million - $4.55 Million
-101,445 Reduced 15.31%
561,172 $20.9 Million
Q4 2022

Feb 13, 2023

BUY
$33.21 - $62.69 $722,981 - $1.36 Million
21,770 Added 3.4%
662,617 $23.1 Million
Q3 2022

Nov 14, 2022

SELL
$53.92 - $71.7 $87,188 - $115,938
-1,617 Reduced 0.25%
640,847 $35.9 Million
Q2 2022

Aug 11, 2022

BUY
$38.49 - $76.21 $557,912 - $1.1 Million
14,495 Added 2.31%
642,464 $33.3 Million
Q1 2022

May 11, 2022

SELL
$58.27 - $118.99 $2.35 Million - $4.81 Million
-40,398 Reduced 6.04%
627,969 $45.6 Million
Q4 2021

Feb 10, 2022

BUY
$100.76 - $138.36 $17.6 Million - $24.2 Million
174,640 Added 35.37%
668,367 $79 Million
Q3 2021

Nov 12, 2021

BUY
$132.37 - $176.78 $65.4 Million - $87.3 Million
493,727 New
493,727 $66.2 Million

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.15B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.